NCT05215808View on ClinicalTrials.gov

SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

September 30, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

RBN-3143

Oral Administration of tablets

Trial Locations (6)

8011

RECRUITING

New Zealand Clinical Research (NZCR), Christchurch

Unknown

RECRUITING

Veracity Clinical Research, Woolloongabba

RECRUITING

Optimal Clinical Trials, Auckland

RECRUITING

Waitemata Clinical Research, Auckland

RECRUITING

Southern Clinical Trials Tasman, Nelson

SA 5000

RECRUITING

CMAX Clinical Research Pty Ltd, Adelaide

All Listed Sponsors
lead

Ribon Therapeutics, Inc.

INDUSTRY